Fortress Biotech Inc  

(Public, NASDAQ:FBIO)   Watch this stock  
Find more results for NASDAQ:CNDO
2.94
-0.04 (-1.34%)
After Hours: 2.94 0.00 (0.00%)
Sep 28, 4:47PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.91 - 3.01
52 week 2.10 - 4.66
Open 3.01
Vol / Avg. 53,373.00/95,237.00
Mkt cap 143.09M
P/E     -
Div/yield     -
EPS -1.39
Shares 48.67M
Beta 1.12
Inst. own 17%
Nov 7, 2016
Q3 2016 Fortress Biotech Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Aug 9, 2016
Q2 2016 Fortress Biotech Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin -734.93% -6243.69%
Operating margin -678.74% -5855.27%
EBITD margin - -5852.26%
Return on average assets -64.77% -51.83%
Return on average equity -125.28% -76.04%
Employees 34 -
CDP Score - -

Address

2 Gansevoort St Fl 9
NEW YORK, NY 10014-1667
United States - Map
+1-781-6524500 (Phone)
+1-781-6524545 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Fortress Biotech, Inc., formerly Coronado Biosciences, Inc., is a biopharmaceutical company. The Company is involved in the development of immunotherapy agents for the treatment of autoimmune diseases and cancer. Its sole product candidate is CNDO-109. The Company is also focused on acquiring, developing and commercializing pharmaceutical and biotechnology products. The Company's product, CNDO-109, is a lysate (disrupted Closteroviridae (CTV)-1 cells, cell membrane fragments, cell proteins and other cellular components) that activates donor Natural Killer (NK) cells. CTV-1 is a leukemic cell line re-classified as a T-cell acute lymphocytic leukemia (ALL). The Company holds the license to develop and commercialize CNDO-109 to activate NK cells for the treatment of cancer-related and other conditions, and a non-exclusive license to certain clinical data solely for use in the Investigational new drug (IND) for CNDO-109. The Company is conducting the Phase I clinical studies of CNDO-109.

Officers and directors

Lindsay A. Rosenwald M.D. Chairman of the Board, President, Chief Executive Officer
Age: 61
Bio & Compensation  - Reuters
Eric K. Rowinsky M.D. Vice Chairman of the Board
Age: 59
Bio & Compensation  - Reuters
Lucy Lu M.D. Chief Financial Officer, Executive Vice President
Age: 39
Bio & Compensation  - Reuters
Michael S. Weiss Executive Vice Chairman - Strategic Development
Age: 50
Bio & Compensation  - Reuters
George C. Avgerinos Ph.D. Senior Vice President - Biologics Operations
Age: 62
Bio & Compensation  - Reuters
Malcolm Hoenlein Ph.D. Director
Age: 71
Bio & Compensation  - Reuters
David J. Barrett CPA, Independent Director
Age: 39
Bio & Compensation  - Reuters
Jimmie Harvey Jr., M.D. Independent Director
Age: 63
Bio & Compensation  - Reuters
J. Jay Lobell J.D. Independent Director
Age: 52
Bio & Compensation  - Reuters